Physician profile
Christopher P Ip
NPI 1932233616
$5,421.47
in general payments reported to CMS, 2019-2025
31 companies · $856 in 2025
The $856 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $579 · 2020: $397 · 2021: $977 · 2022: $807 · 2023: $1,000 · 2024: $804 · 2025: $856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,537 · Education: $99.99 · Travel and Lodging: $24.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,536.56 |
| Education | $99.99 |
| Travel and Lodging | $24.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,534.88 | 2019-2025 | Xtandi, Myrbetriq |
| Teleflex LLC | $674.82 | 2021-2024 | Urolift |
| Ferring Pharmaceuticals INC. | $560.74 | 2019-2025 | Adstiladrin |
| Abbvie INC. | $385.39 | 2019-2025 | |
| Antares Pharma, INC. | $311.86 | 2020-2025 | Xyosted, Nocdurna, Tlando |
| Accord Healthcare, INC. | $266.26 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $223.82 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $142.07 | 2019-2023 | |
| Tolmar, INC. | $123.97 | 2023-2025 | Jatenzo |
| Angiodynamics, INC. | $107.26 | 2023 | Nanoknife |
| Karl Storz Endoscopy-America | $101.44 | 2019-2023 | |
| Neotract INC. | $96.13 | 2019-2020 | |
| Medtronic, INC. | $87.00 | 2021-2025 | Altaviva |
| Urovant Sciences INC | $71.88 | 2021-2022 | |
| Allergan, INC. | $67.03 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $63.12 | 2023-2025 | Ams 700, Spaceoar Vue System - 10ml |
| Palette Life Sciences, INC. | $62.50 | 2022-2023 | |
| Myovant Sciences INC. | $62.47 | 2021-2022 | |
| Halozyme INC | $56.75 | 2023 | |
| Blue Earth Diagnostics | $53.15 | 2019-2025 | Posluma |
| Merck Sharp & Dohme LLC | $49.80 | 2022-2025 | Keytruda |
| Myriad Genetic Laboratories, INC. | $47.83 | 2024-2025 | Myrisk, Prolaris |
| Tolmar Pharmaceuticals, INC. | $47.05 | 2019-2022 | |
| Urogen Pharma, INC. | $43.04 | 2025 | |
| Alnylam Pharmaceuticals INC. | $40.13 | 2023 | Givlaari |
| Calyxo, INC. | $28.55 | 2025 | Cvac Aspiration System |
| Coloplast Corp | $28.11 | 2022 | |
| Immunitybio, INC. | $27.63 | 2025 | |
| Metuchen Pharmaceuticals | $22.86 | 2019 | |
| Pfizer INC. | $18.97 | 2019 | |
| Sun Pharmaceutical Industries INC. | $14.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ip listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.